Monday, 21 Oct 2019

You are here

Generic Price Fixing Alleged by State Prosecutors

The NY Times and 60 Minutes have reported that Connecticut, along with 43 other states, filed a mega-lawsuit accusing the generic drug makers of a massive, systematic conspiracy to bilk consumers out of billions of dollars. (Citation source:

The lawsuit is based on years of research that claims leading drug companies,  including Teva, Pfizer (Greenstone), Novartis, Mylan and Heritage, have prospectively conspired to inflate the prices of generic drugs, by as much as 1,000 percent, to maximize profits.

The industrywide scheme affected the prices of more than 100 generic drugs, according to the complaint, including lamivudine-zidovudine, budesonide, fenofibrate, amphetamine-dextroamphetamine, nystatin, oral antibiotics, blood thinners, cancer drugs, contraceptives and antidepressants.

On 60 Minutes William Tong, the Connecticut Attorney General, states that between 2013 and  2014, a bottle of doxycycline shot up 8,281 percent from $20 to more than $1800. A bottle of asthma medication, albuterol sulfate, jumped more than 4000 percent, from $11 to $434. And pravastatin, a cholesterol drug, up more than 500 percent, from $27 a bottle to $196.

Court documents have laid out the brazen price-fixing scheming of more than a dozen generic drug companies and the executives responsible for sales, marketing and pricing.  Despite their efforts to avoid written records of collusion, involved parties coordinated their efforts at at industry meals, parties, golf outings and other networking events. The attorney general of Connecticut says the corrdinated efforts are further documented by phone and text messages, emails, and sales reports.  The complaint alleges that these drug companies illegally conspired to increase prices and to thwart competition.  

Generic drugs were established by Congress in1984 to create competition and limit drug prices once they are off patent.  But recent findings show that 1,215 generics, many of them the most prescribed drugs, jumped on average more than 400 percent in a single year.

Most evidence stems from collusive activity between July 2013 to January 2015, when Teva raised prices on nearly 400 formulations of 112 generic drugs.  While Teva Pharmaceuticals appears to be a leader in the conspiracy, numerous companies have latched on to industrywide price increases. 

Teva has recently denied any involvement in price fixing. 

In February 2018, Teva increased the price of penicillamine to 18,375 (100 pills) to manage Wilson disease and other conditions. Another generic maker, Mylan, was behind the public outrage over the price raising for the life-saving drug EpiPen (from $100 to over $600 for 2 syringes).

The new lawsuit is a more expansive version of a similar suit filed by the previous Connecticut attorney general in December 2016 in the Federal District Court for the Eastern District of Pennsylvania.  That suit is currently tied up on court.

The Connecticut AG asserts that "this conspiracy has caused billions and billions of dollars in damages to the people of Connecticut and states across the country. And we're gonna take them on in court and hold them accountable. And they're gonna pay for the money they stole from the American people".

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

ACR Responds to CY2020 Medicare Physician Fee Schedule Proposed Rule

Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d

Parenteral Out-Performs Oral Weekly Methotrexate

A systematic review in PLOS suggests that parenteral MTX therapy is more successful than oral MTX in achieving optimal disease activity control. 

ACR Survey Shows Half of Patients Cannot Afford Treatments

Americans living with rheumatic disease face significant healthcare challenges, according to a national patient survey released this week by the American College of Rheumatology. More than 1,500 U.S. adults living with rheumatic disease responded to the survey, which asked a range of questions related to healthcare access, affordability and lifestyle. Key findings include that even though 90 percent of respondents reported having health insurance coverage, nearly 60 percent said they had difficulty affording their medications or treatments in the past year.

Medical Use of Cannabis in 2019

JAMA has published an overview of cannabis and its medical uses. Although nearly 10% of cannabis users in the United States report using it for medicinal purposes, there is insufficient evidence to support the use of medical cannabis for most conditions for which its use is advocated or advised. Nevertheless, there is increase in favoring the public availability of cannabis, largely for the management of more than 50 medical conditions.

Steroid Sparing Effects of Methotrexate and Mycophenolate in Uveitis

Patients with noninfectious uveitis (intermediate, posterior uveitis, or panuveitis) often require high dose corticosteroids and therefore may need steroid-sparing DMARD therapy. The FAST study investigated the corticosteroid-sparing effect of methotrexate or mycophenolate mofetil in adults with noninfectious uveitis.